GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » EPS (Diluted)

Simcere Pharmaceutical Group (HKSE:02096) EPS (Diluted) : HK$0.29 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group EPS (Diluted)?

Simcere Pharmaceutical Group's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.66. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.29.

Simcere Pharmaceutical Group's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.66. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.30.

Simcere Pharmaceutical Group's EPS without NRI for the six months ended in Dec. 2023 was HK$0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.30.

During the past 3 years, the average EPS without NRIGrowth Rate was 22.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Simcere Pharmaceutical Group's highest 3-Year average EPS without NRI Growth Rate was 22.00% per year. The lowest was -10.90% per year. And the median was 3.20% per year.


Simcere Pharmaceutical Group EPS (Diluted) Historical Data

The historical data trend for Simcere Pharmaceutical Group's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group EPS (Diluted) Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial 0.43 0.30 0.71 0.40 0.30

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.02 0.38 0.94 -0.66

Competitive Comparison of Simcere Pharmaceutical Group's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simcere Pharmaceutical Group's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's PE Ratio falls into.



Simcere Pharmaceutical Group EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Simcere Pharmaceutical Group's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(781.79-0)/2608.534
=0.30

Simcere Pharmaceutical Group's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1706.171-0)/2598.118
=-0.66

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Simcere Pharmaceutical Group  (HKSE:02096) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Simcere Pharmaceutical Group EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group (HKSE:02096) Business Description

Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Executives
Wang Xi 2305 Beneficiary of a trust
Ren Jinsheng 2202 Interest of your spouse
Right Wealth Holdings Limited 2501 Other
Wang Xi 2501 Other
Simcere Investments Group Limited 2501 Other
Excel Investments Group Limited 2501 Other
Simcere Pharmaceutical Holding Limited 2501 Other
Simcere Holding Limited 2501 Other
Artking Global Limited 2501 Other
Ren Zhen 2501 Other
Ren Yong 2501 Other
Ren Weidong 2501 Other
Peng Suqin 2501 Other
P&h Holdings Group Ltd. 2501 Other
Li Shimeng 2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines